BRD9500

BRD9500 is an orally active phosphodiesterases 3 ( PDE3 ) inhibitor with IC 50 s of 10 and 27 nM for PDE3A and PDE3B , respectively. Antitumor activity In Vitro BRD9500 is a DNMDP analog. DNMDP potently and selectively inhibits PDE3A and PDE3B and kills cancer cells by inducing PDE3A/B interactions with SFLN12. BRD9500 exhibits an EC 50 of 1 nM for SK-MEL-3 melanoma cell line viability. BRD9500 exhibits an EC 50 of 1.6 nM for HeLa viability. BRD9500 (10 μM; 8 hours) stabilizes the PDE3A-SLFN12 interaction in HeLa cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HeLa cells Concentration: 10 μM Incubation Time: 8 hours Result: SLFN12 coimmunoprecipitation was analyzed by immunoblotting with an anti-V5 antibody to detect the SLFN12-V5 fusion protein. The SLFN12-V5 was clearly detected with the anti-V5 antibody. In Vivo BRD9500 (10, 20, and 50 mg/kg; orally) inhibits SK-MEL-3 melanoma growth in mice . BRD9500 shows high plasma levels in mice after iv (1 mg/kg) as well as po (2 mg/kg) dosing over eight hours making it a valuable candidate for in vivo xenograft testing . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NMRI nude mice bearing SK-MEL-3 melanoma cells tumor xenografts Dosage: 10, 20, and 50 mg/kg Administration: Orally at 10 and 20 mg/kg twice daily (2QD) and at 50 mg/kg once per day (QD). Result: Achieved the strongest antitumor activity at 50 mg/kg. All treatments were well tolerated without critical body weight loss or toxicities. Form:Solid IC50& Target:PDE3A 10 nM (IC 50 ) PDE3B 27 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet